“
TL;DR
This is a case report of a 17-year-old boy with Crohn's disease who had a seizure during an infliximab infusion. The patient had undetectable drug levels and moderate anti-TNF antibody levels at the time of the event.
JPGN Reports · 3 authors, 1 centre
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This is a case report of a 17-year-old boy with Crohn's disease who had a seizure during an infliximab infusion. The patient had undetectable drug levels and moderate anti-TNF antibody levels at the time of the event.
This paper describes a single pediatric case report of a 17-year-old male with moderate-to-severe ileocolonic Crohn's disease maintained on infliximab therapy. The patient developed an acute, witnessed generalized seizure with postictal confusion within 4 minutes of starting an infusion. He had no prior neurologic history, and evaluations including brain MRI were normal. Testing 2 days post-episode showed undetectable infliximab drug levels (<0.1 μg/mL) and moderate anti-TNF antibody levels (15.2 U/mL). The event resolved, and the patient transitioned to adalimumab without recurrence. The authors discuss this as a potential neurologic adverse event possibly related to drug immunogenicity, noting that patients with antibodies are more likely to develop infusion reactions.